A novel anti-tissue factor monoclonal antibody with anticoagulant potency derived from synthesized multiple antigenic peptide through blocking FX combination with TF

Peng, Zhuo Chun; Cai, Xu; Zhang, Yu Gao; Kong, De Sheng; Guo, Hong Shen; Wang, Liang; Tang, Qi; Song, Hou Yan; Ma, Da

doi:10.1016/j.thromres.2007.03.001

Cited by 4 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is 1,000 times stronger inhibition than the rat anti-mouse monoclonal antibody, 1H1 [Kirchhofer et al, 2005]. It also slowed Factor Xa production concentration-dependently in the TF activity assay with an IC 50 value of 100 nM, 10 times stronger than that observed for the monoclonal anti-TF antibody, TF4A12 [Peng et al, 2007]. It is also a stronger inhibitor than other orally available TF/FVIIa complex inhibitors [Miura et al, 2007].…”

Section: Discussionmentioning

confidence: 74%

Development of an inhibitory antibody fragment to human tissue factor using phage display technology

Meiring

Vermeulen

Badenhorst

2009

Drug Development Research

View full text Add to dashboard Cite

Tissue factor is involved in the etiology of thrombotic diseases initiating the thrombosis associated with the inflammation that occurs during infection. The prevention of blood coagulation and inflammation is of primary importance in a number of pathological situations. A single-chain variable antibody fragment of molecular weight of 26 kD that inhibits the action of human tissue factor was selected by phage display technology, purified and tested for its tissue factor inhibitory effect, purified on a protein A column, and its purity evaluated on SDS-PAGE. The effects of the antibody fragment on prothrombin times, Factor Xa production, and thrombin generation were assessed with increasing fragment concentrations, using chromogenic and fluorometric substrates. The antibody fragment dose-dependently prolonged the prothrombin time (IC 50 5 0.5 mM) and delayed the lag phase before the thrombin generation burst and the peak thrombin concentration in the thrombin generation assay. The effect on thrombin generation was more pronounced in thrombophilic plasma than in normal plasma. Antibody-based tissue factor inhibitors therefore may provide an effective treatment for thrombotic disease without serious bleeding complications. Drug Dev Res 70 : 199-205, 2009.

show abstract

Section: Discussionmentioning

confidence: 74%

Development of an inhibitory antibody fragment to human tissue factor using phage display technology

Meiring

Vermeulen

Badenhorst

2009

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…The development of anticoagulants for use in extracorporeal circuits covers a vast array of compounds, ranging from thrombin-directed aptamers [102], recombinant tick anticoagulant peptide [103,104], pentasaccharide [105,106], recombinant nematode anticoagulant [107], anti-TF antibodies [108] and active site inhibited factor VIIa [109] to recombinant tissue factor pathway inhibitors [110]. The unique conditions and local environment that define extracorporeal circuits create major challenges in pharmacotherapy application and investigation.…”

Section: Future Directionsmentioning

confidence: 99%

Anticoagulant therapy during cardiopulmonary bypass

Yavari

Becker

2008

J Thromb Thrombolysis

View full text Add to dashboard Cite

The prothrombotic and hemostatic-altering environment that characterizes cardiac surgery in general and cardiopulmonary bypass (CPB) in particular is unparalleled in medicine, causing, in an alarming number of patients, both thrombotic and hemorrhagic events. Fundamentally, the primary objective of anticoagulant therapy during CPB is to prevent thrombin generation and its attendant prothrombotic, proinflammatory, and vascular effects. Though anticoagulation with unfractionated heparin has been the standard of care for more than a half-century for patients undergoing cardiac surgery, inherent limitations, and an unfavorable safety profile will increasingly stimulate the investigation and development of more safe and effective therapies.

show abstract

Dynamic changes of tissue factor pathway inhibitor type 2 associated with IL-1β and TNF-α in the development of murine acute lung injury

Mao

Lin

et al. 2008

Thrombosis Research

View full text Add to dashboard Cite

A novel anti-tissue factor monoclonal antibody with anticoagulant potency derived from synthesized multiple antigenic peptide through blocking FX combination with TF

Cited by 4 publications

References 21 publications

Development of an inhibitory antibody fragment to human tissue factor using phage display technology

Development of an inhibitory antibody fragment to human tissue factor using phage display technology

Anticoagulant therapy during cardiopulmonary bypass

Dynamic changes of tissue factor pathway inhibitor type 2 associated with IL-1β and TNF-α in the development of murine acute lung injury

Contact Info

Product

Resources

About